Apricus Bioscience's Wholly-Owned Subsidiary NexMed Signs Exclusive German Collaboration for Vitaros for Erectile Dysfunction

Loading...
Loading...
Apricus Biosciences, Inc.
APRI
announced today that its wholly-owned subsidiary NexMed Inc. has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to market Apricus Bio's Vitaros® drug for the treatment of erectile dysfunction. Pursuant to the collaboration, Sandoz will pay Apricus Bio up to €21 million – divided into a fixed upfront payment and specific regulatory and commercial milestones – as well as, double digit royalties on net sales. Total upfront and milestone payments represent approximately $28 million based on today's exchange rate.
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...